Medical technology company Xcision Medical Systems has signed a contract for its GammaPod stereotactic radiotherapy breast cancer system with an Italian hospital.
Azienda Universitaria Integrata in Udine, Italy, plans to use the system to offer shorter courses of radiotherapy for women with breast cancer, according to the firm. The hospital also will join the GammaPod Research Consortium, which was founded by the University of Maryland in Baltimore, U.S. to investigate postoperative and preoperative applications for the device, Xcision said.
GammaPod is cleared for use in the U.S. by the U.S. Food and Drug Administration (FDA). It is for investigational use only in Europe, pending compliance with the Medical Device Directive. Tema Sinergie is Xcision's Italian distributor for the device.
